| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0053 | 0.9 |
| mRNA | Crizotinib | FIMM | pan-cancer | AAC | 0.026 | 0.9 |
| mRNA | BRD-K63431240 | CTRPv2 | pan-cancer | AAC | 0.0049 | 0.9 |
| mRNA | Nilotinib | CTRPv2 | pan-cancer | AAC | -0.005 | 0.9 |
| mRNA | BRD-K33514849 | CTRPv2 | pan-cancer | AAC | -0.016 | 0.9 |
| mRNA | Nilotinib | FIMM | pan-cancer | AAC | -0.023 | 0.9 |
| mRNA | BRD6340 | CTRPv2 | pan-cancer | AAC | 0.0043 | 0.9 |
| mRNA | AP-24534 | FIMM | pan-cancer | AAC | 0.021 | 0.9 |
| mRNA | pifithrin-alpha | CTRPv2 | pan-cancer | AAC | 0.0045 | 0.9 |
| mRNA | XL-184 | GDSC1000 | pan-cancer | AAC | -0.004 | 0.9 |